CN1612735A - 抗疟治疗药物的新用途 - Google Patents
抗疟治疗药物的新用途 Download PDFInfo
- Publication number
- CN1612735A CN1612735A CNA028267923A CN02826792A CN1612735A CN 1612735 A CN1612735 A CN 1612735A CN A028267923 A CNA028267923 A CN A028267923A CN 02826792 A CN02826792 A CN 02826792A CN 1612735 A CN1612735 A CN 1612735A
- Authority
- CN
- China
- Prior art keywords
- hydrogen
- group
- antimalarial compound
- antimalarial
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims (56)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34587201P | 2001-11-09 | 2001-11-09 | |
US60/345,872 | 2001-11-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1612735A true CN1612735A (zh) | 2005-05-04 |
CN1289086C CN1289086C (zh) | 2006-12-13 |
Family
ID=23356861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028267923A Expired - Fee Related CN1289086C (zh) | 2001-11-09 | 2002-11-12 | 抗疟治疗药物的新用途 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20040167162A1 (zh) |
EP (1) | EP1450803A4 (zh) |
JP (1) | JP2005512998A (zh) |
CN (1) | CN1289086C (zh) |
AU (1) | AU2002363443B2 (zh) |
CA (1) | CA2466338C (zh) |
HK (1) | HK1075619A1 (zh) |
IL (1) | IL161821A0 (zh) |
MX (1) | MXPA04004393A (zh) |
WO (1) | WO2003039546A1 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102481252A (zh) * | 2009-06-23 | 2012-05-30 | 吕旿荣 | 含有羟基氯喹的用于痔核治疗的局部投药用注射剂组合物 |
CN103027915A (zh) * | 2011-09-29 | 2013-04-10 | 中国医学科学院基础医学研究所 | 氯喹治疗和氯丙嗪预防肺感染和损伤的用途 |
CN103705516A (zh) * | 2013-12-11 | 2014-04-09 | 武汉威立得生物医药有限公司 | 氯喔星在制备治疗或预防流感病毒感染的药物中的应用 |
CN111658648A (zh) * | 2020-02-03 | 2020-09-15 | 中国人民解放军军事科学院军事医学研究院 | 4-氨基喹啉类化合物在治疗冠状病毒感染方面的应用 |
WO2021217574A1 (en) * | 2020-04-30 | 2021-11-04 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Treatment or prevention of coronaviridae infection |
CN114908062A (zh) * | 2020-02-16 | 2022-08-16 | 北京化工大学 | 盐酸甲氟喹或甲氟喹在制备治疗冠状病毒感染性疾病的药物的用途 |
CN115869311A (zh) * | 2022-12-30 | 2023-03-31 | 湖北工业大学 | MefloquineHydrochloride在制备抗腺病毒ADV7药物中的应用 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7084157B2 (en) * | 2002-05-17 | 2006-08-01 | Rajeev Raut | Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation |
WO2004085402A1 (en) * | 2003-03-27 | 2004-10-07 | Council Of Scientific And Industrial Research | Ring-substituted 8-aminoqunoline derivates as antimalarial agents |
US20070134596A1 (en) * | 2005-12-08 | 2007-06-14 | Adrian Lungu | Photosensitive printing element having nanoparticles and method for preparing the printing element |
CN101466380A (zh) * | 2006-02-16 | 2009-06-24 | 麦克莱恩医院 | 治疗帕金森病的方法和组合物 |
KR101828553B1 (ko) * | 2016-04-15 | 2018-02-13 | 한국화학연구원 | 신규한 벤조싸이오펜 유도체, 이의 약학적으로 허용 가능한 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물 |
ES2844927T3 (es) | 2016-06-28 | 2021-07-23 | Hopitaux Paris Assist Publique | Derivados de primaquina para la utilización en la prevención y/o el tratamiento de trastornos asociados al virus herpes gamma |
US20210244705A1 (en) * | 2020-02-07 | 2021-08-12 | Centre For Digestive Diseases | Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection |
US11007187B1 (en) * | 2020-03-25 | 2021-05-18 | Therapeutica Borealis Oy | Medicine for Covid-19 and treatment |
WO2021191496A1 (en) * | 2020-03-25 | 2021-09-30 | Therapeutica Borealis Oy | Medicine for covid-19 and treatment |
US11638722B2 (en) | 2020-03-25 | 2023-05-02 | Therapeutica Borealis Oy C/O Avance Attorneys Ltd. | Medicine for Covid-19 and treatment |
US11278602B2 (en) | 2020-03-25 | 2022-03-22 | Therapeutica Borealis Oy | Medicine for Covid-19 and treatment |
WO2021204717A1 (en) * | 2020-04-06 | 2021-10-14 | Oxandia Ltd | Aminoquinolines for treating coronavirus infections |
EP3892275A1 (en) * | 2020-04-08 | 2021-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Aerosolization of hcq or its metabolites for the treatment of lung infections |
CA3176360A1 (en) * | 2020-04-21 | 2021-10-28 | Noam Cohen | Quinine and its use to generate innate immune response |
CA3180854A1 (en) * | 2020-04-24 | 2021-10-28 | Thomas Julius Borody | Products of manufacture and methods for treating, ameliorating or preventing microbial infections |
US20230165851A1 (en) * | 2020-04-27 | 2023-06-01 | Immunologik Gmbh | 6'-methoxycinchonan-9-ols for the treatment of coronaviral infections |
AU2021339013A1 (en) * | 2020-09-14 | 2023-04-06 | Philip Morris Products S.A. | Pharmaceutical composition comprising hydroxychloroquine and uses thereof |
DE102021000717A1 (de) * | 2021-02-12 | 2022-08-18 | Forschungszentrum Jülich GmbH | Quinacrin als lnhibitor viraler Cysteinproteasen und/oder Serinproteasen |
WO2023023651A1 (en) * | 2021-08-19 | 2023-02-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Quinacrine and derivatives thereof for treatment of viral infections |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4181725A (en) * | 1977-05-02 | 1980-01-01 | The Regents Of The University Of Michigan | Method for alleviating psoriasis |
US4496549A (en) * | 1983-01-17 | 1985-01-29 | American Cyanamid Company | Treatment of malaria with antibiotics |
US5153202A (en) * | 1988-06-30 | 1992-10-06 | Davis Michael H | Method of inhibiting the activity of human immuno deficiency virus (HIV) in vivo |
US5376359A (en) * | 1992-07-07 | 1994-12-27 | Glaxo, Inc. | Method of stabilizing aerosol formulations |
US5827681A (en) * | 1996-12-20 | 1998-10-27 | University Technology Corporation | Rapid detection and drug sensitivity of malaria |
US6572858B1 (en) * | 1999-04-30 | 2003-06-03 | Apt Pharmaceuticals, Llc | Uses for anti-malarial therapeutic agents |
-
2002
- 2002-11-12 US US10/293,770 patent/US20040167162A1/en not_active Abandoned
- 2002-11-12 JP JP2003541837A patent/JP2005512998A/ja active Pending
- 2002-11-12 MX MXPA04004393A patent/MXPA04004393A/es not_active Application Discontinuation
- 2002-11-12 CN CNB028267923A patent/CN1289086C/zh not_active Expired - Fee Related
- 2002-11-12 IL IL16182102A patent/IL161821A0/xx unknown
- 2002-11-12 WO PCT/US2002/036309 patent/WO2003039546A1/en active Application Filing
- 2002-11-12 CA CA002466338A patent/CA2466338C/en not_active Expired - Fee Related
- 2002-11-12 AU AU2002363443A patent/AU2002363443B2/en not_active Ceased
- 2002-11-12 EP EP02802902A patent/EP1450803A4/en not_active Withdrawn
-
2005
- 2005-09-06 HK HK05107810A patent/HK1075619A1/xx not_active IP Right Cessation
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102481252A (zh) * | 2009-06-23 | 2012-05-30 | 吕旿荣 | 含有羟基氯喹的用于痔核治疗的局部投药用注射剂组合物 |
CN103027915A (zh) * | 2011-09-29 | 2013-04-10 | 中国医学科学院基础医学研究所 | 氯喹治疗和氯丙嗪预防肺感染和损伤的用途 |
CN103687599A (zh) * | 2011-09-29 | 2014-03-26 | 中国医学科学院基础医学研究所 | 氯喹或氯丙嗪或其衍生物或它们的混合物在制备用于治疗和/或预防肺感染和损伤的药物中的用途 |
CN103705516A (zh) * | 2013-12-11 | 2014-04-09 | 武汉威立得生物医药有限公司 | 氯喔星在制备治疗或预防流感病毒感染的药物中的应用 |
CN111658648A (zh) * | 2020-02-03 | 2020-09-15 | 中国人民解放军军事科学院军事医学研究院 | 4-氨基喹啉类化合物在治疗冠状病毒感染方面的应用 |
WO2021155651A1 (zh) * | 2020-02-03 | 2021-08-12 | 中国人民解放军军事科学院军事医学研究院 | 4-氨基喹啉类化合物在治疗冠状病毒感染方面的应用 |
CN114908062A (zh) * | 2020-02-16 | 2022-08-16 | 北京化工大学 | 盐酸甲氟喹或甲氟喹在制备治疗冠状病毒感染性疾病的药物的用途 |
CN114908062B (zh) * | 2020-02-16 | 2023-10-20 | 北京化工大学 | 盐酸甲氟喹或甲氟喹在制备治疗冠状病毒感染性疾病的药物的用途 |
WO2021217574A1 (en) * | 2020-04-30 | 2021-11-04 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Treatment or prevention of coronaviridae infection |
CN115515935A (zh) * | 2020-04-30 | 2022-12-23 | 中美华世通生物医药科技(武汉)股份有限公司 | 冠状病毒感染的治疗或预防 |
CN115869311A (zh) * | 2022-12-30 | 2023-03-31 | 湖北工业大学 | MefloquineHydrochloride在制备抗腺病毒ADV7药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
HK1075619A1 (en) | 2005-12-23 |
CA2466338A1 (en) | 2003-05-15 |
IL161821A0 (en) | 2005-11-20 |
CA2466338C (en) | 2010-01-12 |
AU2002363443B2 (en) | 2006-02-16 |
MXPA04004393A (es) | 2005-09-12 |
WO2003039546A1 (en) | 2003-05-15 |
EP1450803A4 (en) | 2008-09-03 |
EP1450803A1 (en) | 2004-09-01 |
CN1289086C (zh) | 2006-12-13 |
US20040167162A1 (en) | 2004-08-26 |
JP2005512998A (ja) | 2005-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1289086C (zh) | 抗疟治疗药物的新用途 | |
US20110275584A1 (en) | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss | |
JP5937060B2 (ja) | 呼吸器ウイルス感染症の治療方法 | |
CN1747937A (zh) | 预防hiv感染的嘧啶衍生物 | |
AU2002363443A1 (en) | New uses for anti-malarial therapeutic agents | |
CN1147766A (zh) | 治疗感染的药物 | |
CN1382044A (zh) | 细胞因子抑制性抗炎药在鼻病毒感染中的用途 | |
JP6857617B2 (ja) | インフルエンザウイルスの複製の阻害剤 | |
CN1891701A (zh) | 杂芳环缩氨基硫脲类化合物及其衍生物和它们在制备抗肿瘤药物中的应用 | |
CN100350908C (zh) | 新颖的抗变态反应抗炎组合物 | |
CN111743899A (zh) | 硝唑尼特及其活性形式替唑尼特在治疗SARS-CoV-2感染中的应用 | |
JP2023534723A (ja) | コロナウイルス感染症の治療におけるベンフルメトール及びその誘導体の応用 | |
CN1103782A (zh) | 眼局部给药的抗变态反应的药物组合物 | |
CN1345725A (zh) | 治疗慢性阻塞性肺部疾病的二氮杂䓬并吲哚 | |
CN1328463A (zh) | 17-酮甾类化合物及其衍生物、代谢产物和前体在治疗丙型肝炎病毒和其他披膜病毒中的应用 | |
CN113304166A (zh) | 核苷类化合物在治疗冠状病毒感染性疾病中的用途 | |
CN111658648A (zh) | 4-氨基喹啉类化合物在治疗冠状病毒感染方面的应用 | |
CN1672731A (zh) | 一种用于肺部给药的干扰素粉雾剂及其制备方法 | |
CN1500487A (zh) | 左西替利嗪伪麻黄碱复方口服制剂及制备方法 | |
US20100028298A1 (en) | Interferon type i supporting compounds | |
EP2558097B1 (en) | Vapendavir for the alleviation of symptoms of asthma in a subject having a HRV infection | |
CN1110299C (zh) | 三氮唑核苷气雾剂及其制备方法 | |
WO2019001173A1 (zh) | sCD100蛋白在制备慢性HBV感染治疗药物中的应用 | |
Kwok | Drug Repurposing and Dosage Form Development of Anti-COVID-19 | |
CN111789839A (zh) | 利托那韦在治疗SARS-CoV-2感染方面的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1075619 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: APT PHARMACEUTICAL CO.,LTD. Free format text: FORMER OWNER: LAOLUNJIALU Effective date: 20051209 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20051209 Address after: Arizona, USA Applicant after: APT Pharmaceutical Inc. Address before: Wisconsin Applicant before: Charous Lauren |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1075619 Country of ref document: HK |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061213 Termination date: 20121112 |